Morgan Stanley assumed coverage of Acadia Pharmaceuticals (ACAD) with an Equal Weight rating and $20 price target The firm sees patent protection for Nuplazid extending to 2030 and models about $2.4B in residuals post loss of exclusivity, noting that it models 11% net product sales growth in 2025 to about $1.1B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Balanced Outlook for ACADIA Pharmaceuticals Amid Uncertain Long-term Growth Prospects
- Acadia Pharmaceuticals, Saniona announce results from ACP-711 cohorts
- ACADIA Pharmaceuticals: Promising Growth and Strategic Advancements Justify Buy Rating
- ACADIA Pharmaceuticals Reports Strong Earnings and Growth Plans
- Positive Outlook for ACADIA Pharmaceuticals Driven by Strong Daybue Sales and Promising Pipeline